| 13.16 -0.18 (-1.35%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.35 | 1-year : | 17.41 |
| Resists | First : | 14 | Second : | 14.9 |
| Pivot price | 13.62  |
|||
| Supports | First : | 12.53 | Second : | 10.43 |
| MAs | MA(5) : | 13.58 |
MA(20) : | 13.59 |
| MA(100) : | 10.88 |
MA(250) : | 8.91 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 34.4 |
D(3) : | 44.6 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 14.9 | Low : | 3.91 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EYPT ] has closed above bottom band by 19.4%. Bollinger Bands are 33.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.44 - 13.52 | 13.52 - 13.58 |
| Low: | 12.67 - 12.78 | 12.78 - 12.85 |
| Close: | 13.02 - 13.18 | 13.18 - 13.29 |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Tue, 14 Oct 2025
EyePoint Announces Pricing of Public Offering - EyePoint Pharmaceuticals
Tue, 14 Oct 2025
JPMorgan and Partners Manage Offering for EYPT - GuruFocus
Tue, 14 Oct 2025
EyePoint (EYPT) Launches $150 Million Public Share Offering - GuruFocus
Tue, 14 Oct 2025
EyePoint Pharmaceuticals (EYPT) Announces $150 Million Public Of - GuruFocus
Tue, 14 Oct 2025
Eyepoint Pharmaceuticals stock falls after $150 million share offering - Investing.com
Tue, 14 Oct 2025
Eyepoint Pharmaceuticals Inc files for mixed shelf size not disclosed - SEC filing - MarketScreener
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 4.263e+007 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 8,450 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8714e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 166.8 % |
| Return on Equity (ttm) | -37.8 % |
| Qtrly Rev. Growth | 5.19e+007 % |
| Gross Profit (p.s.) | -22.19 |
| Sales Per Share | -37.54 |
| EBITDA (p.s.) | -6.78731e+007 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -191 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.36 |
| Price to Cash Flow | 7.26 |
| Dividend | 0 |
| Forward Dividend | 8e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|